Within the TME, STING pathway activation leads to increases in Type I interferon signaling, the maturation of antigen presenting cells (APCs), and improved recruitment of T cells into tumors in support of slowed disease progression or tumor regression (9). This evidence concerns the gene STING1 and neoplasm.